Royalties from all six areas of life sciences
We work with asset managers and royalty funds that buy royalties or lend against them. We find royalties, prepare the information you need to review them and introduce you to the holders.
How we work with asset managers and royalty funds
- 1 Find
We search filings, patent records and our network across six areas of life sciences, and approach the holders.
- 2 Prepare
We collect the licence terms, the payment history and available sales data for each royalty, and identify the consents needed from partners and lenders.
- 3 Bundle
Where royalties are too small to fund one by one, we group them into portfolios large enough to fund.
- 4 Introduce
We introduce holders to asset managers and royalty funds, which carry out their own due diligence, agree terms with the holder and make their own investment decisions.
We also audit royalty books that asset managers and royalty funds already hold. More on portfolio audits
Our own AI models read the documents where royalties are written down
Most royalties are never announced. They sit in licence agreements, company filings, court records and patent assignments. Our models, trained on licensing deals, extract the terms and map who pays royalties to whom.
- Company filings in the US, Japan, Korea and China
- Court records, where royalty rates are sometimes unredacted
- Patent records and changes of ownership
- Approved products in all six areas
- Royalty rate, tiers and caps
- Territory and term
- Who pays whom, across agreements
- Royalties that were never announced, such as a large company paying a small private licensor
- Royalty tails: payments that continue after a cap is reached or the main patents expire
- Royalties on one region, such as Japan or Europe
- Smaller royalties, including those held by universities and hospitals
- Royalties outside pharma
Where royalties are financed today
In pharma, holders regularly sell royalties or borrow against them. In the other five areas the instrument works the same way, but few deals are made public.
| Area | Sales | Share | Deals |
|---|---|---|---|
| Pharma and vaccines | About $1.6tn | 71% | 128 |
| Medtech | Over $500bn | 22% | 2 |
| Crops and seeds | About $120bn | 5% | 0 |
| Animal health | About $39bn | 2% | 1 |
Sales show where royalties can arise; the share of sales that carries a royalty varies by area. Sales are for the latest year available, 2022 to 2024, and rounded; shares use $500bn for medtech. The pharma figure includes vaccines other than for COVID-19. Animal health covers only the 20 largest companies, so its share is understated. Digital health has no reliable figure for global sales and is left out. Deals are those publicly disclosed and listed in the tracker, classified by Capital for Cures by the product area of the royalty.